Cargando…

Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021

There is uncertainty about the seroprevalence of anti-SARS-CoV-2 antibodies in the general population of Austria and about the waning of antibodies over time. We conducted a seroepidemiological study between June 2020 and September 2021, enrolling blood donors aged 18–70 years across Tyrol, Austria...

Descripción completa

Detalles Bibliográficos
Autores principales: Siller, Anita, Seekircher, Lisa, Wachter, Gregor A., Astl, Manfred, Tschiderer, Lena, Pfeifer, Bernhard, Gaber, Manfred, Schennach, Harald, Willeit, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954543/
https://www.ncbi.nlm.nih.gov/pubmed/35336975
http://dx.doi.org/10.3390/v14030568
_version_ 1784676119159504896
author Siller, Anita
Seekircher, Lisa
Wachter, Gregor A.
Astl, Manfred
Tschiderer, Lena
Pfeifer, Bernhard
Gaber, Manfred
Schennach, Harald
Willeit, Peter
author_facet Siller, Anita
Seekircher, Lisa
Wachter, Gregor A.
Astl, Manfred
Tschiderer, Lena
Pfeifer, Bernhard
Gaber, Manfred
Schennach, Harald
Willeit, Peter
author_sort Siller, Anita
collection PubMed
description There is uncertainty about the seroprevalence of anti-SARS-CoV-2 antibodies in the general population of Austria and about the waning of antibodies over time. We conducted a seroepidemiological study between June 2020 and September 2021, enrolling blood donors aged 18–70 years across Tyrol, Austria (participation rate: 84.0%). We analyzed serum samples for antibodies against the spike or the nucleocapsid proteins of SARS-CoV-2. We performed a total of 47,363 samples taken from 35,193 individuals (median age, 43.1 years (IQR: 29.3–53.7); 45.3% women; 10.0% with prior SARS-CoV-2 infection). Seroprevalence increased from 3.4% (95% CI: 2.8–4.2%) in June 2020 to 82.7% (95% CI: 81.4–83.8%) in September 2021, largely due to vaccination. Anti-spike IgG seroprevalence was 99.6% (95% CI: 99.4–99.7%) among fully vaccinated individuals, 90.4% (95% CI: 88.8–91.7%) among unvaccinated individuals with prior infection and 11.5% (95% CI: 10.8–12.3%) among unvaccinated individuals without known prior infection. Anti-spike IgG levels were reduced by 44.0% (95% CI: 34.9–51.7%) at 5–6 months compared with 0–3 months after infection. In fully vaccinated individuals, they decreased by 31.7% (95% CI: 29.4–33.9%) per month. In conclusion, seroprevalence in Tyrol increased to 82.7% in September 2021, with the bulk of seropositivity stemming from vaccination. Antibody levels substantially and gradually declined after vaccination or infection.
format Online
Article
Text
id pubmed-8954543
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89545432022-03-26 Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021 Siller, Anita Seekircher, Lisa Wachter, Gregor A. Astl, Manfred Tschiderer, Lena Pfeifer, Bernhard Gaber, Manfred Schennach, Harald Willeit, Peter Viruses Article There is uncertainty about the seroprevalence of anti-SARS-CoV-2 antibodies in the general population of Austria and about the waning of antibodies over time. We conducted a seroepidemiological study between June 2020 and September 2021, enrolling blood donors aged 18–70 years across Tyrol, Austria (participation rate: 84.0%). We analyzed serum samples for antibodies against the spike or the nucleocapsid proteins of SARS-CoV-2. We performed a total of 47,363 samples taken from 35,193 individuals (median age, 43.1 years (IQR: 29.3–53.7); 45.3% women; 10.0% with prior SARS-CoV-2 infection). Seroprevalence increased from 3.4% (95% CI: 2.8–4.2%) in June 2020 to 82.7% (95% CI: 81.4–83.8%) in September 2021, largely due to vaccination. Anti-spike IgG seroprevalence was 99.6% (95% CI: 99.4–99.7%) among fully vaccinated individuals, 90.4% (95% CI: 88.8–91.7%) among unvaccinated individuals with prior infection and 11.5% (95% CI: 10.8–12.3%) among unvaccinated individuals without known prior infection. Anti-spike IgG levels were reduced by 44.0% (95% CI: 34.9–51.7%) at 5–6 months compared with 0–3 months after infection. In fully vaccinated individuals, they decreased by 31.7% (95% CI: 29.4–33.9%) per month. In conclusion, seroprevalence in Tyrol increased to 82.7% in September 2021, with the bulk of seropositivity stemming from vaccination. Antibody levels substantially and gradually declined after vaccination or infection. MDPI 2022-03-09 /pmc/articles/PMC8954543/ /pubmed/35336975 http://dx.doi.org/10.3390/v14030568 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Siller, Anita
Seekircher, Lisa
Wachter, Gregor A.
Astl, Manfred
Tschiderer, Lena
Pfeifer, Bernhard
Gaber, Manfred
Schennach, Harald
Willeit, Peter
Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021
title Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021
title_full Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021
title_fullStr Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021
title_full_unstemmed Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021
title_short Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021
title_sort seroprevalence, waning and correlates of anti-sars-cov-2 igg antibodies in tyrol, austria: large-scale study of 35,193 blood donors conducted between june 2020 and september 2021
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954543/
https://www.ncbi.nlm.nih.gov/pubmed/35336975
http://dx.doi.org/10.3390/v14030568
work_keys_str_mv AT silleranita seroprevalencewaningandcorrelatesofantisarscov2iggantibodiesintyrolaustrialargescalestudyof35193blooddonorsconductedbetweenjune2020andseptember2021
AT seekircherlisa seroprevalencewaningandcorrelatesofantisarscov2iggantibodiesintyrolaustrialargescalestudyof35193blooddonorsconductedbetweenjune2020andseptember2021
AT wachtergregora seroprevalencewaningandcorrelatesofantisarscov2iggantibodiesintyrolaustrialargescalestudyof35193blooddonorsconductedbetweenjune2020andseptember2021
AT astlmanfred seroprevalencewaningandcorrelatesofantisarscov2iggantibodiesintyrolaustrialargescalestudyof35193blooddonorsconductedbetweenjune2020andseptember2021
AT tschidererlena seroprevalencewaningandcorrelatesofantisarscov2iggantibodiesintyrolaustrialargescalestudyof35193blooddonorsconductedbetweenjune2020andseptember2021
AT pfeiferbernhard seroprevalencewaningandcorrelatesofantisarscov2iggantibodiesintyrolaustrialargescalestudyof35193blooddonorsconductedbetweenjune2020andseptember2021
AT gabermanfred seroprevalencewaningandcorrelatesofantisarscov2iggantibodiesintyrolaustrialargescalestudyof35193blooddonorsconductedbetweenjune2020andseptember2021
AT schennachharald seroprevalencewaningandcorrelatesofantisarscov2iggantibodiesintyrolaustrialargescalestudyof35193blooddonorsconductedbetweenjune2020andseptember2021
AT willeitpeter seroprevalencewaningandcorrelatesofantisarscov2iggantibodiesintyrolaustrialargescalestudyof35193blooddonorsconductedbetweenjune2020andseptember2021